EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluating the SARS-CoV-2 spike glycoprotein as a molecular target for therapeutic development

Brandon H. Adame-Velasco, Pablo Octavio-Aguilar, Luis H. Mendoza-Huizar, Liliana M. Aguilar-Castro

INNOSC Theranostics and Pharmacological Sciences · 2024

DOI: 10.36922/itps.1651 ↗

Kurz gefasst

Fachartikel in der Zeitschrift INNOSC Theranostics and Pharmacological Sciences, 2024. Verfasst von Brandon H. Adame-Velasco und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The SARS-CoV-2 virus gains entry into host cells by binding its spike glycoprotein (S-glycoprotein) to the angiotensin 2 receptor. This viral protein contains several conserved regions, such as the receptor binding domain region, making it an ideal target for treating COVID-19. Notably, the majority of existing vaccines elicit antigenic reaction by targeting this protein epitope. This study evaluated the binding affinities of 44 different drugs against the SARS-CoV-2 S-glycoprotein, considering their toxicity profiles and previous clinical studies at different testing stages. Our results revealed that maraviroc and estradiol benzoate exhibited high affinities (−7.7 and −7.6 kcal mol−1, respectively), while other ligands, such as indinavir and ritonavir, showed affinity at lower levels. Among the drugs with high affinity, toxicity levels ranged from harmful if swallowed (300 mg/kg < LD50 < 2000 mg/kg) to non-toxic (LD50 > 5000 mg/kg), with only three having undergone clinical testing, yielding promising or controversial results. Furthermore, emtricitabine and docosanol, previously explored as COVID-19 treatments, exhibited the lowest affinities (−4.7 and −3.9 kcal mol−1, respectively), with associated harmful effects if swallowed. These results provide essential information about drug interaction against the SARS-CoV-2 S-glycoprotein and potential treatment pathways for COVID-19.

Zitieren

APA

Adame-Velasco, B. H., Octavio-Aguilar, P., Mendoza-Huizar, L. H., & Aguilar-Castro, L. M. (2024). Evaluating the SARS-CoV-2 spike glycoprotein as a molecular target for therapeutic development. INNOSC Theranostics and Pharmacological Sciences. https://doi.org/10.36922/itps.1651

Vancouver

Adame-Velasco BH, Octavio-Aguilar P, Mendoza-Huizar LH, Aguilar-Castro LM. Evaluating the SARS-CoV-2 spike glycoprotein as a molecular target for therapeutic development. INNOSC Theranostics and Pharmacological Sciences. 2024. doi:10.36922/itps.1651

BibTeX
@article{AdameVelasco2024,
  author = {Adame-Velasco, Brandon H. and Octavio-Aguilar, Pablo and Mendoza-Huizar, Luis H. and Aguilar-Castro, Liliana M.},
  title = {Evaluating the SARS-CoV-2 spike glycoprotein as a molecular target for therapeutic development},
  journal = {INNOSC Theranostics and Pharmacological Sciences},
  year = {2024},
  doi = {10.36922/itps.1651}
}
Kostenlos starten →